Subject category:
Strategy and General Management
Published by:
International Institute for Management Development (IMD)
Length: 10 pages
Data source: Published sources
Share a link:
https://casecent.re/p/128458
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
This is part of a case series. In 2013, US-based Gilead Sciences launched a miracle remedy for Hepatitis C Sovaldi cured 90% of patients with a particular type of hepatitis in 12-weeks rather than the year it usually took, with greatly reduced side effects. Sovaldi generated great excitement worldwide. The only problem was its price. At $84,500 for a course of treatment, it was beyond the means of most patients. Advocacy groups had successfully won patent concessions from pharma companies including Gilead for HIV/AIDS treatments. Once again they launched major campaigns demanding that all patients be able to access this new drug based on need rather than ability to pay. Competitors, doctors, insurers, governments and patients all had their reasons to support the adoption of Sovaldi. The dynamics among these players would heavily impact Gilead’s future as well as the lives of millions of patients.
Location:
Industry:
Size:
Revenue of USD24,890 million, 7,000 employees
Subject category:
Strategy and General Management
Published by:
International Institute for Management Development (IMD)
Length: 6 pages
Data source: Published sources
About
Abstract
This is part of a case series. In 2013, US-based Gilead Sciences launched a miracle remedy for Hepatitis C Sovaldi cured 90% of patients with a particular type of hepatitis in 12-weeks rather than the year it usually took, with greatly reduced side effects. Sovaldi generated great excitement worldwide. The only problem was its price. At $84,500 for a course of treatment, it was beyond the means of most patients. Advocacy groups had successfully won patent concessions from pharma companies including Gilead for HIV/AIDS treatments. Once again they launched major campaigns demanding that all patients be able to access this new drug based on need rather than ability to pay. Competitors, doctors, insurers, governments and patients all had their reasons to support the adoption of Sovaldi. The dynamics among these players would heavily impact Gilead’s future as well as the lives of millions of patients.
Settings
Location:
Industry:
Size:
Revenue of USD24,890 million, 7,000 employees
Related
Subject category:
Strategy and General Management
Published by:
International Institute for Management Development (IMD)
Length: 6 pages
Data source: Published sources